232 related articles for article (PubMed ID: 20212180)
1. Physician visits prior to treatment for clinically localized prostate cancer.
Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D
Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180
[TBL] [Abstract][Full Text] [Related]
2. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer.
Fowler FJ; McNaughton Collins M; Albertsen PC; Zietman A; Elliott DB; Barry MJ
JAMA; 2000 Jun; 283(24):3217-22. PubMed ID: 10866869
[TBL] [Abstract][Full Text] [Related]
3. United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region.
McNaughton Collins M; Barry MJ; Zietman A; Albertsen PC; Talcott JA; Walker Corkery E; Elliott DB; Fowler FJ
Urology; 2002 Oct; 60(4):628-33. PubMed ID: 12385923
[TBL] [Abstract][Full Text] [Related]
4. The prostate cancer treatment bazaar: comment on "Physician visits prior to treatment for clinically localized prostate cancer".
Barry MJ
Arch Intern Med; 2010 Mar; 170(5):450-2. PubMed ID: 20212181
[No Abstract] [Full Text] [Related]
5. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
[TBL] [Abstract][Full Text] [Related]
6. Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns.
Bekelman JE; Suneja G; Guzzo T; Pollack CE; Armstrong K; Epstein AJ
J Urol; 2013 Jul; 190(1):97-101. PubMed ID: 23399652
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Orihuela E; Goodwin JS
J Clin Oncol; 2007 Dec; 25(34):5359-65. PubMed ID: 18048816
[TBL] [Abstract][Full Text] [Related]
8. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1).
Schymura MJ; Kahn AR; German RR; Hsieh MC; Cress RD; Finch JL; Fulton JP; Shen T; Stuckart E
BMC Cancer; 2010 Apr; 10():152. PubMed ID: 20403178
[TBL] [Abstract][Full Text] [Related]
10. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States.
Sylvester J; Grimm P; Blasco J; Meier R; Spiegel J; Heaney C; Cavanagh W
Urology; 2001 Aug; 58(2 Suppl 1):65-70. PubMed ID: 11502452
[TBL] [Abstract][Full Text] [Related]
11. Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer.
Goulart BH; Reyes CM; Fedorenko CR; Mummy DG; Satram-Hoang S; Koepl LM; Blough DK; Ramsey SD
J Oncol Pract; 2013 Jan; 9(1):42-50. PubMed ID: 23633970
[TBL] [Abstract][Full Text] [Related]
12. Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey.
Ariane MM; Ploussard G; Rebillard X; Malavaud B; Rischmann P; Hennequin C; Mongiat-Artus P
World J Urol; 2015 Nov; 33(11):1741-7. PubMed ID: 25822706
[TBL] [Abstract][Full Text] [Related]
13. Association between urologist characteristics and radiation oncologist consultation for patients with locoregional prostate cancer.
Quek RG; Ward KC; Master VA; Lin CC; Portier KM; Virgo KS; Lipscomb J
J Natl Compr Canc Netw; 2015 Mar; 13(3):303-9. PubMed ID: 25736007
[TBL] [Abstract][Full Text] [Related]
14. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
15. Trends and black/white differences in treatment for nonmetastatic prostate cancer.
Klabunde CN; Potosky AL; Harlan LC; Kramer BS
Med Care; 1998 Sep; 36(9):1337-48. PubMed ID: 9749657
[TBL] [Abstract][Full Text] [Related]
16. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.
Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A
Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823
[TBL] [Abstract][Full Text] [Related]
17. Trends and quality of care in outpatient visits to generalist and specialist physicians delivering primary care in the United States, 1997-2010.
Edwards ST; Mafi JN; Landon BE
J Gen Intern Med; 2014 Jun; 29(6):947-55. PubMed ID: 24567201
[TBL] [Abstract][Full Text] [Related]
18. Urologists' referral and radiation oncologists' treatment patterns regarding high-risk prostate cancer patients receiving radiotherapy within 6 months after radical prostatectomy: A prospective cohort analysis.
Egger S; Smith DP; Brown BB; Kneebone AB; Dominello A; Brooks AJ; Young J; Xhilaga M; Haines M; O'Connell DL
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):134-143. PubMed ID: 31793211
[TBL] [Abstract][Full Text] [Related]
19. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
[TBL] [Abstract][Full Text] [Related]
20. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
J Natl Cancer Inst; 2006 Jun; 98(12):839-45. PubMed ID: 16788157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
